= Bioassay parallelism equivalence margin
A \b[bioassay parallelism equivalence margin] is a prespecified range of curve-shape differences considered small enough for the intended <relative biological potency> comparison. It turns “sufficiently similar” into a testable criterion. A nonsignificant difference test does not establish that the possible difference lies inside this range.
For an original local model on log concentration $z$, take reference and test responses $y_R=a_R+b_Rz$ and $y_T=a_T+b_Tz$, with positive slopes. At a response level $y$, their horizontal separation is
$$
\Delta z(y)=\frac{y-a_R}{b_R}-\frac{y-a_T}{b_T}.
$$
The change in log potency across a response band of width $W$ is therefore $W(1/b_R-1/b_T)$. This relates a slope-equivalence margin to the response range over which potency must remain approximately constant.
Suppose the allowed change in the equal-effect concentration ratio across that band is at most a factor 1.1 in either direction. The log-scale requirement is
$$
W\left|\frac1{b_R}-\frac1{b_T}\right|\le\log1.1.
$$
With stipulated $W=b_R=1$ in the chosen response units, let $s=b_T/b_R$. Then
$$
\frac1{1+\log1.1}\le s\le\frac1{1-\log1.1},
$$
approximately 0.9130–1.1054. This is an original conditional tolerance calculation, not a universal assay specification. Changing the response range or tolerated potency variation changes the margin.
An <equivalence test> asks whether an appropriately constructed uncertainty interval is contained within the acceptance range. An illustrative slope-ratio interval 0.95–1.05 lies inside the calculated range, while 0.88–1.12 does not. A slope criterion alone does not validate different upper or lower plateaus in a nonlinear curve. <Response-range calibration of a bioassay equivalence margin> should therefore accompany the chosen response model and experimental range.
A primary historical example is a 2017 collaborative rituximab-standard study. Its analysts assessed equivalence of upper asymptote, asymptote difference and slope parameters, and derived study-specific bounds from coded duplicate preparations. The report explicitly limits those bounds to that study rather than routine laboratory validity criteria.<Report on a Collaborative Study for Proposed Candidate 1st International Standard for the biological activities of Rituximab by Sandra Prior and others>[WHO/BS/2017.2309, printed pp. 8 and 10–11, Statistical analysis and Assay validity]{ref}
This example illustrates a distinction between empirical reference-against-reference variation and a margin justified by the intended measurement. Document which argument sets each acceptance range. Include uncertainty from plate layout, biological replication and <serial dilution>; a narrow fitted interval under an incomplete noise model can overstate the evidence for <bioassay parallelism>. Predefine the analysis so that observed test-versus-reference disagreement does not silently determine its own acceptance criterion.
Back to article page
